Home World News Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC... World News Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 623 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Coronavirus and COVID-19: What People With Cancer Need to Know June 21, 2020 EMA Recommends Extension of Indications for Nivolumab and Ipilimumab September 25, 2020 Frederick National Laboratory for Cancer Research: A Unique Resource for the... March 28, 2023 Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients... December 1, 2021 Load more HOT NEWS 5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His... Does Sugar Feed Cancer? Trastuzumab Deruxtecan Prolongs PFS After Endocrine-Based Therapy in Patients with HR-positive,... EMA Recommends Extension of Therapeutic Indications for Olaparib
